AGEN NASDAQ
Agenus Inc.
1W: +3.6%
1M: -29.5%
3M: +0.3%
YTD: +105.9%
1Y: +60.6%
3Y: -62.8%
5Y: -93.4%
$6.65
+0.49 (+7.95%)
Weekly Expected Move ±14.6%
$4
$5
$6
$7
$8
Credit Risk of going bust: higher than 86% of companies Debt: 11.9% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the second-riskiest tenth, about 1 in 87 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.26 (down 96%), Agenus Inc. would be worth roughly what it owes.
Total debt $40.7M against a stock market value of $300.3M.
Distance to default 2.02 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $30.1M (short-term plus half of long-term), stock volatility 106.2%; Altman Z'' -40.96. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.26 (down 96%), Agenus Inc. would be worth roughly what it owes.
Total debt $40.7M against a stock market value of $300.3M.
Distance to default 2.02 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $30.1M (short-term plus half of long-term), stock volatility 106.2%; Altman Z'' -40.96. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.30
Neutral
1 bullish
2 neutral
0 bearish
Articles (7d)
3
Daily Sentiment (7 Days)
Articles (100)
At a glance: stocks gapping up premarket
Biggest stock movers Monday: XCNR, SGRY, AGEN
Agenus reports response rate in colon cancer trial
Agenus Inc. (NASDAQ:AGEN) Stock Has Consensus Price Target of $24.50 According to Analysts
What's next for personalized mRNA cancer vaccines?
At a glance: stocks gapping up premarket
Agenus (NASDAQ:AGEN) Shares Cross Above 200-Day Moving Average – Should You Sell?
10 small-cap healthcare stocks with the strongest momentum grades
At a glance: stocks gapping down premarket
Bank of New York Mellon Corp Makes New Investment in Agenus Inc. $AGEN
Earnings Week Ahead: ORCL, ADBE, KR, GME, CHWY, and more
Agenus (NASDAQ:AGEN) Stock Crosses Above 200-Day Moving Average – Here’s Why
HC Wainwright Issues Negative Outlook for Agenus Earnings
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates
Agenus (AGEN) Earnings Expected to Grow: Should You Buy?
Do Options Traders Know Something About Agenus Stock We Don't?
What is HC Wainwright’s Estimate for Agenus Q2 Earnings?
AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot
Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last?
Agenus stock gains after private placement of up to $340M
Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report?
AGEN Early Access Revenues Signal a New Path Ahead of Approval
Is Agenus Stock a Hold Amid Valuation and Funding Risks?
AGEN BOT+BAL: What the BATTMAN Trial Means for mCRC
IBRX Stock Outlook After Q1 Results and a New FDA Review
ImmunityBio: Anktiva Explained and What Comes Next
AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential?
How Agenus' Pipeline Progress Unlock Its Next Growth Phase
Russell 3000 Shuffle: Ocugen, Nektar slated to join among healthcare stocks; Nano-X to drop off
AGEN Stock Dips 19.4% in a Month: Time to Buy, Hold or Sell?
Agenus (AGEN) Q1 Earnings and Revenues Miss Estimates
RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus
Here are the major earnings before the open Monday
Earnings week ahead: BABA, CSCO, PLUG, AMAT, JD, and more
Mettler-Toledo Q1 Earnings Top Estimates, Sales Increase Y/Y
Ironwood Stock Down Despite Q1 Earnings and Revenue Beat
VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings
Nektar Q1 Earnings & Revenues Lag Estimates, Pipeline in Focus
PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Agenus Q1 2026 Earnings Preview
Philips Q1 Earnings and Revenues Decrease Year over Year, Shares Up
Viatris Q1 EPS Beats Estimates, Revenues up 8% Driven by Greater China
ADMA Q1 EPS Jumps 73% Y/Y, Revenues Slip, 2026 View Down
WAT Q1 Earnings Beat Estimates, BD Acquisition Aids Revenues
Zoetis Q1 Earnings Lag Estimates, 2026 View Cut, Stock Down
TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 View
Mirum's Q1 Earnings & Revenues Beat Estimates, 2026 View Raised
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue Estimates
Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises
Repligen's Q1 Earnings & Revenues Beat Estimates, Stock Rises
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?
Viatris Gears Up to Report Q1 Earnings: What's in the Cards?
VRTX's Q1 Earnings Beat Estimates, New Products Aid Sales Growth
Pfizer Beats on Q1 Earnings, New & Acquired Drugs Drive Sales Growth
Are Options Traders Betting on a Big Move in Agenus Stock?
Catalyst Pharmaceutics to Report Q1 Earnings: Is a Beat in the Cards?
STERIS' Q4 Earnings on Deck: What's in Store for the Stock?
Agenus (AGEN) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Charles River Gears Up for Q1 Earnings: What's in the Cards?
CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised
Zoetis Gears Up to Report Q1 Earnings: Is a Beat in the Cards?
Here's How IDEXX Laboratories Is Placed Ahead of Q1 Earnings
Q32 Bio Gears Up to Report Q1 Earnings: What's in the Cards?
BHC Q1 Earnings Miss Estimates, Sales Grow on Salix & Solta Strength
BMY's Q1 Earnings Top Estimates, Breyanzi, Camzyos Drive Sales
CVS Q1 Earnings Preview: Health Services Likely to Lead Performance
Bio-Techne's Q3 Earnings on Deck: What's in Store for the Stock?
Vertex Gears Up to Report Q1 Earnings: What Investors Can Expect
Novartis Q1 Earnings & Revenues Miss Estimates, Stock Down
Here's How Henry Schein Is Placed Ahead of Q1 Earnings
Moderna Gears Up to Report Q1 Earnings: Here's What to Expect
Will Lower Premiums Affect Cigna's Q1 Earnings? Key Insights Here
Will Robust Exome and Genome Revenues Lift GeneDx's Q1 Earnings?
CRISPR Therapeutics to Report Q1 Earnings: Is a Beat in the Cards?
Will Declining Memberships Weigh on Centene's Q1 Earnings?
AbbVie's TrenibotE Receives FDA CRL Due to Manufacturing Issues
Brokerages Set Agenus Inc. (NASDAQ:AGEN) Price Target at $14.50
Will Increasing Operating Costs Affect Humana's Q1 Earnings?
Here's Why Agenus (AGEN) is a Strong Momentum Stock
AMRX Announces Kashiv BioSciences Buyout, Solid Q1 Preliminary Results
Resmed's Q3 Earnings on Deck: What's in Store for the Stock?
MRK Down as Triplet Therapy Fails to Meet Goal in Kidney Cancer Study
MRK Down as Triplet Therapy Fails to Meet Goal in Kidney Cancer Study
MRK's sBLAs for Keytruda Combo in Bladder Cancer Get FDA Priority Tag
BIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock Up
Align Technology's Q1 Earnings on Deck: Here's What to Expect
Labcorp Gears Up to Report Q1 Earnings: What's in Store?
Viking Therapeutics Gears Up for Q1 Earnings: Here's What to Expect
Edwards Lifesciences' Q1 Earnings on Deck: Here's What to Expect
Is Agenus (AGEN) Outperforming Other Medical Stocks This Year?
Here's How Zimmer Biomet Is Placed Ahead of Q1 Earnings
Will Declining Premiums & Higher MCR Weigh on MOH Q1 Earnings?
Will Robust Cardiovascular Performance Fuel BSX's Q1 Earnings?
TGTX Completes Enrollment in Phase III Study on Subcutaneous Briumvi
TMO Q1 Earnings Preview: Will Life Sciences Solutions Lead Results?
Here's How Quest Diagnostics Is Placed Ahead of Q1 Earnings
ALLO Rises on Strong MRD Clearance With Cema-Cel in ALPHA3 Study
Agenus (AGEN) is a Great Momentum Stock: Should You Buy?
HC Wainwright Issues Positive Forecast for Agenus Earnings